According to recent research from London, the United Kingdom, " Institutional tuberculosis (TB) transmission is an important public health problem highlighted by the HIV/AIDS pandemic and the emergence of multidrug- and extensively drug-resistant TB. Effective TB infection control measures are urgently needed.
Researchers from the newly-established VGTI Florida and the University of Montreal have uncovered a possible method for eradicating HIV infection in the human body. The researchers have also revealed new information which demonstrates how HIV persists in the body - even in patients receiving drug treatments - and how the virus continues to replicate itself in individuals undergoing treatment.
A discovery by a team of Canadian and American researchers could provide new ways to fight HIV-AIDS. According to a new study published in Nature Medicine, HIV-AIDS could be treated through a combination of targeted chemotherapy and current Highly Active Retroviral (HAART) treatments.
Prolonged use of highly active antiretroviral therapy (HAART) is associated with insulin resistance in HIV-1-positive patients. Small animal models that recapitulate the long-term effects of HAART may facilitate the identification of therapeutic agents to suppress these side effects.
According to recent research published in the Chinese Medical Journal, " Virus with nucleoside reverse transcriptase inhibitors (NRTIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs) resistant mutations show different evolution tendencies when the anti-viral therapies are interrupted. Understanding the replication fitness of drug-resistant virus is important for the study of the prevalence of drug-resistance.
In higher eukaryotes, introns are usually required for efficient pre-mRNA processing. However, some viruses have alternative approaches involving posttranscriptional regulatory elements (PREs) to enhance intronless heterologous gene expression through enabling stability and 30 end formation, and to facilitate the nucleocytoplasmic export of unspliced mRNAs.
No patient demonstrated any adverse effects attributed to these higher doses. Low serum concentrations of antituberculous drugs, which suggest malabsorption, are common among patients with advanced HIV who also have tuberculosis but can be overcome with higher doses.
HLA-DR2 subtyping was carried out by polymerase chain reaction-based sequence-specific oligonucleotide probe method. Overrepresentation of HLA-DRB1*1501 in HIV-positive PTB-negative (HIV+PTB-) patients (p=0.004, P(c)=0.06) and -DRB1*1502 in HIV-positive PTB-positive (HIV+PTB+) patients (p=0.019) was observed as compared to healthy controls.
Once a cell is infected with HIV-1, activation of the virus's gene generates a large HIV-1 RNA molecule known as the RNA genome. This is then transported from the cell nucleus to the inner surface of the plasma membrane. The RNA genome can produce both structural proteins and enzymes, but once it arrives at the plasma membrane it can also assemble into new copies of the virus that actually bud out of the cell.
Those in the United States living with HIV/AIDS are more likely to use marijuana than those in Kenya, South Africa or Puerto Rica to alleviate their symptoms, according to a new study published in Clinical Nursing Research. Those who did use marijuana rate it as effective as prescribed or over the counter (OTC) medicines for the majority of common symptoms, once again raising the issue that therapeutic marijuana use merits further study and consideration among policy makers.
“When approving new technologies, the FDA should focus less on the general population and more on the people who will actually use these technologies,” said co-author A. David Paltiel, PhD, of the Yale School of Medicine. “The disconnect between approved indication and actual use is stark.”
Latent HIV genes can be 'smoked out' of human cells. The so-called 'shock and kill' technique, described in a preclinical study in BioMed Central's open access journal Retrovirology, might represent a new milestone along the way to the discovery of a cure for HIV/AIDS.
According to recent research from Plymouth, the United Kingdom, "There has been much debate regarding the optimum treatment for syphilis in HIV-positive patients. There has been a shift in expert opinion in the UK towards using two doses of benzathine penicillin G one week apart regardless of HIV status.
A highly antiretroviral treatment-experienced man was commenced on a new regimen containing enfuvirtide. Prophylaxis for Pneumocystis jirovecii pneumonia was started using trimethoprim/sulphamethoxazole (TMP-STX) simultaneously.
The objective was to evaluate the effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to TruvadaA (R) (TVD) in virologically suppressed HIV patients. We carried out an open-label, multicentre, non-controlled study of HIV patients on a stable regimen including TDF-3TC who switched from TDF-3TC to TVD
Global and national programs to prevent vertical (mother-to-child) transmission are in disarray and governments are falling seriously short of their goals, leading to hundreds of thousands of needless HIV infections annually, according to new on-the-ground research from six countries published in the latest Missing the Target report -- "Failing Women, Failing Children: HIV, Vertical Transmission and Women's Health" -- from the International Treatment Preparedness Coalition (ITPC), to be released during the 62nd World Health Assembly (WHA) in Geneva.
The new device is a vaginal ring that releases multiple types of non-hormonal agents and microbicides, which would prevent conception as well as sexually transmitted HIV infection.
Although federal law does not mandate Medicaid termination for prisoners, 90 percent of states have implemented policies that withdraw inmates' enrollment upon incarceration, which the authors say leaves a vulnerable population uninsured following release.
Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus-1 (HIV-1) and hepatitis C virus. Little is known about the impact of combination NRTIs and HIV-1 coinfection on HBV viral kinetic parameters following the initiation of HBV-active highly active antiretroviral therapy (HAART).
These findings therefore highlight the importance of considering beta-cell viability and function when assessing loss of glycemic control and the course of development of diabetes in HIV+ subjects receiving a protease inhibitor.
A new UCLA AIDS Institute study suggests the answer lies in a protein called interleukin-21 (IL-21), a powerful molecule released by immune cells during chronic infection. Published May 7 in the online edition of Science, the finding could explain how the immune system limits viral replication, restricting a virus's spread through the body.
According to a study from London, the United Kingdom, "The extent and possibilities of spread of the HIV epidemic are not fully understood in Pakistan. A survey was conducted among men, women and transgender populations selling sex in Rawalpindi (Punjab) and Abbottabad (North West Frontier Province) in order to inform evidence-based programme planning.
Abacavir (ABC) is administered either at 600 mg once daily (ABC 600 mg QD) or 300 mg twice daily (ABC 300 mg BID) in anti-human immunodeficiency virus (anti-HIV) combination therapy. Although ABC plasma pharmacokinetics following each regimen has been well defined, no study has directly compared the regimens with respect to pharmacokinetics of ABC's active intracellular anabolite, carbovir-triphosphate (CBV-TP)," scientists in the United States report.
Scientists may need to rethink the design of drugs meant to block HIV from infecting human cells, according to a study that appears in the May 1st issue of the journal Cell, a Cell Press publication. That's because the new report shows that HIV doesn't enter cells in the way that experts had generally assumed it did.
Lopinavir/ritonavir (LPV/r)-dosed twice daily has demonstrated durable efficacy in antiretroviral-naive and protease inhibitor (PI) -experienced patients. M05-730 compared LPV/r tablets dosed once daily vs. twice daily in antiretroviral-naive subjects," researchers in the United States report.
Thailand began a national antiretroviral (ARV) treatment program in 2000, and all government and some private and university hospitals now provide treatment to eligible HIV-infected patients. We describe program scale-up and patient outcomes from 2000 to 2007," investigators in Nonthaburi, Thailand report.
The AIDS-causing HIV specifically counteracts the mechanisms of human cells that protect these against viral infections – a special viral protein marks protective cellular proteins for their rapid destruction and thus diminishes the cell's supply. A team of researchers in Heidelberg under supervision of virologist Dr. Oliver Keppler demonstrated this mechanism for the first time in cell cultures, thus discovering a target for a novel treatment strategy.
Although numerous drugs are used to treat HIV infection with increasing efficacy, the patient's brain is often infected by the virus and acts as a sanctuary where drugs cannot penetrate due to their low passage through the blood brain barrier. Therefore, the design of new medicine able to reach the brain is extemely challenging," scientists in Chatenay-Malabry, France report.
Damage to patients' immune systems is happening sooner now than it did at the beginning of the HIV epidemic, suggesting the virus has become more virulent, according to a new study in the May 1, 2009 issue of Clinical Infectious Diseases, now available online.
Rifampin (RMP), a first-line antituberculosis drug, reaches serum concentrations well below suggested lower limits when a standard dose of 8-12mg/kg body weight is given to children. A pharmacokinetic study, published in the open access journal BMC Medicine, suggests that a higher dose of 10-20mg/kg may be more appropriate.
Researchers involved in this first-of-its-kind study found that cell-delivered gene transfer has the potential to be a once-only treatment that reduces viral load, preserves the immune system and avoids lifelong antiretroviral therapy.
Approximately 80 percent of HIV-infected Texas prison inmates did not fill an initial prescription for antiretroviral therapy within 30 days of their release from prison, potentially increasing their risk for harmful health consequences because of an interruption of treatment, according to a study in the February 25 issue of JAMA.
This paper summarises tuberculosis (TB) research over almost 30 years in Karonga District, northern Malawi, an area typical of much of rural Africa. The dominant factor has been the human immunodeficiency virus (HIV), which arrived in the district about 1980, leading to an increase in TB incidence to a peak of approximately 65 smear-positive pulmonary cases per 100,000 population in 2000
The efficacy of various antiretroviral (ARV) therapy regimens for human immunodeficiency virus type 2 (HIV-2) infection remains unclear. HIV-2 is intrinsically resistant to the nonnucleoside reverse-transcriptase inhibitors and to enfuvirtide and may also be less susceptible than HIV-1 to some protease inhibitors (PIs).
New research at Oregon Health & Science University's Vaccine and Gene Therapy Institute suggests vaccines that specifically target HIV in the initial stages of infection before it becomes a rapidly replicating, system-wide infection - may be a successful approach in limiting the spread of the disease.
Reliable clinical algorithms that screen for active tuberculosis (TB) in human immunodeficiency virus (HIV) infected people initiating or receiving anti-retroviral treatment (ART) in sub-Saharan Africa could reduce the need for diagnostic procedures. We estimated the utility of six TB-related signs and symptoms, alone or in combination, compared with the Uganda Ministry of Health diagnostic guidelines for participants with prevalent (baseline), early ART (≤3 months on ART) and incident TB (>3 months on ART).
Untreated human immunodeficiency virus (HIV) infection is accompanied by reduced bone mineral density, which appears to be exacerbated by certain HIV protease inhibitors (PIs). The mechanisms leading to this apparent paradox, however, remain unclear.
"Saliva is a potentially important barrier against respiratory viral infection but its mechanism of action is not well studied. We tested the antiviral activities of whole saliva, specific salivary gland secretions, and purified salivary proteins against strains of influenza A virus (IAV) in vitro."
Researchers in the United States conducted a study "To examine the ability of the HIV-Dementia Scale (HDS) and Mini Mental State Exam (MMSE) to detect encephalopathy in adolescents living with human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome (AIDS).
The membrane proximal region (MPR) of the transmembrane subunit, gp41, of the HIV envelope glycoprotein plays a critical role in HIV-1 infection of CD4(+) target cells and CD4-independent mucosal entry. It contains continuous epitopes recognized by neutralizing IgG antibodies 2F5, 4E10 and Z13, and is therefore considered to be a promising target for vaccine design.
In this study, human immunodeficiency virus type 1 (HIV-1)-infected blood donors were evaluated for genetic subtype and drug resistance to determine the prevalence of divergent HIV strains in the US donor population. Subtype was determined by phylogenetic analysis of viral sequences amplified by reverse transcription-polymerase chain reaction.
Traditionally, HIV patients were not considered transplant candidates because survival rates after transplantation were thought to be greatly compromised by the disease, which cripples the body's immune system. Transplant patients also take drugs that suppress their immune systems in order to prevent organ rejection, a regimen thought to further threaten their already fragile immune systems.
The study revealed that a variant of a protein involved in HIV pathogenesis can suppress production of an HIV protein, known as Nef. Nef is required for the human immunodeficiency virus to develop into AIDS through a series of complex events involving viral elements and cellular proteins. Nef has never been a target for drug treatment in HIV patients.
"In countries infected with HIV clade B, some patients develop a rapidly progressive dementia that if untreated results in death. In regions of the world infected with HIV clade C, only milder forms of cognitive impairment have been recognized," scientists in the United States report.
According to a study from Birmingham, the United Kingdom, "Apolipoprotein E ( APOE) alleles have been associated with the severity of, or susceptibility to, infection by various microbes."
Researchers have discovered a potentially important new resistance factor in the battle against HIV: blood types. An international team of researchers from Canadian Blood Services, The Hospital for Sick Children (SickKids) and Lund University in Sweden have discovered that certain blood types are more predisposed to contracting HIV, while others are more effective at fending it off.
High-risk subtypes of HPV have been estimated to be present in 99.7 percent of cervical cancers worldwide. Evidence has shown that women with circumcised partners have a reduced risk for genital cancer. Two new studies sought to discover if HPV infection is more likely to occur in uncircumcised compared with circumcised men.
Recently reported clinical trials in Africa have shown that interventional use of adult male circumcision reduced the risk of HIV infection in heterosexual men. The current U.S. study was able to show that circumcision significantly protected heterosexual African American men. It did so by focusing on subjects who had documented exposure to an HIV-infected female partner
According to recent research from the United States, “The incidence of venous thromboembolism (VTE) in HIV-infected patients is uncertain, and the impact of protease inhibitors on the incidence of VTE is also uncertain, yet important to know to create a database for providing opinion regarding prophylaxis for the prevention of VTE. Data from the National Hospital Discharge Survey (NHDS) were analyzed from 1990 through 2005.”
“CMX001 is a lipid (1-O-hexadecyloxypropyl) conjugate of the phosphonate nucleotide analogue cidofovir (CDV). CDV, which is approved by the FDA for the treatment of cytomegalovirus (CMV)-induced retinitis in AIDS patients, is active against all five families of double-stranded DNA (dsDNA) viruses that cause human morbidity and mortality,” investigators in the United States report.
For the first time, researchers have established a clear link between family rejection of lesbian, gay and bisexual (LGB) adolescents and negative health outcomes in early adulthood. The findings will be published in the January issue of Pediatrics, the journal of the American Academy of Pediatrics, in a peer-reviewed article entitled “Family Rejection as a Predictor of Negative Health Outcomes in White and Latino Lesbian, Gay and Bisexual Young Adults.”
“On the basis of the structural and functional information of anti-HIV peptides from a previous study, we designed an HIV fusion inhibitor named CP32M, a 32-mer synthetic peptide that is highly effective in inhibiting infection by a wide range of primary HIV-1 isolates from multiple genotypes with R5- or dual-tropic (R5X4) phenotype, including a group O virus (BCF02) that is resistant to T20 and C34 (another anti-HIV peptide). Strikingly, CP32M is exceptionally potent (at low picomolar level) against infection by a panel of HIV-1 mutants highly resistant to T20 and C34,” wrote Y.X. He and colleagues, New York Blood Center.
The time has come for immunologists to start weaning themselves from experimental rodents and to embark on a bold, industrial-scale assault on the causes and treatment of specifically human disease, writes immunologist Mark Davis, PhD, in an essay to be published Dec. 19 in Immunity. Davis, director of the Stanford Institute for Immunity, Transplantation and Infection, proposes that the current mouse-centered, small-laboratory approach be supplemented by a broad, industrial-scale "systems biology" approach akin to the one that unraveled the human genome.
Tavis and his collaborators, Rajeev Aurora, Ph.D., and Maureen Donlin, Ph.D., used a mathematical model to draw a map of the viral genome of 94 hepatitis C patients who responded and did not respond to standard therapy. They found a complex web of amino acid interactions in the viral proteins that resembled an airline map, with amino acid hubs that linked to many other amino acids in much the way that certain cities are centers of activity for incoming and outgoing flights.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the Elton John AIDS Foundation UK, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
